TY - JOUR AU - Amantea, MA AU - Forrest, A AU - Northfelt, DW AU - Mamelok, R TI - Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi/'s sarcoma JA - Clin Pharmacol Ther PY - 1997/// VL - 61 SP - 301 EP - 311 PB - Cancer Research Campaign M3 - 10.1016/S0009-9236(97)90162-4 N1 - 10.1016/S0009-9236(97)90162-4 UR - http://dx.doi.org/10.1016/S0009-9236(97)90162-4 ER - TY - GEN AU - Beal, SL AU - Sheiner, LB AU - Boeckmann, AJ TI - JA - PY - 1994/// VL - SP - EP - PB - Cancer Research Campaign ER - TY - JOUR AU - Bronchud, MH AU - Margison, JM AU - Howell, A AU - Lind, M AU - Lucas, SB AU - Wilkinson, PM TI - Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer JA - Cancer Chemother Pharmacol PY - 1990/// VL - 25 SP - 435 EP - 439 PB - Cancer Research Campaign ER - TY - JOUR AU - Bruno, R AU - Vivier, N AU - Vergniol, JC AU - DePhillips, SL AU - Montay, G AU - Sheiner, LB TI - A population pharmacokinetic model for taxotere: model building and validation JA - J Pharmacokinet Biopharm PY - 1996/// VL - 24 SP - 153 EP - 172 PB - Cancer Research Campaign M3 - 10.1007/BF02353487 N1 - 10.1007/BF02353487 UR - http://dx.doi.org/10.1007/BF02353487 ER - TY - JOUR AU - Chabot, GG AU - Abigerges, D AU - Catimel, G AU - Culine, S AU - Deforni, R AU - Extra, JM AU - Mahjoubi, H AU - Herait, P AU - Armand, JP AU - Bugat, R AU - Clavel, M AU - Marty, ME TI - Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during Phase I trials JA - Ann Oncol PY - 1995/// VL - 6 SP - 141 EP - 151 PB - Cancer Research Campaign ER - TY - JOUR AU - Chatelut, E AU - Canal, P AU - Brunner, V AU - Chevreau, C AU - Pujol, A AU - Boneu, A AU - Roche, H AU - Houin, G AU - Bugat, R TI - Prediction of carboplatin clearance from standard morphological and biological patient characteristics JA - J Natl Cancer Inst PY - 1995/// VL - 87 SP - 573 EP - 580 PB - Cancer Research Campaign M3 - 10.1093/jnci/87.8.573 N1 - 10.1093/jnci/87.8.573 UR - http://dx.doi.org/10.1093/jnci/87.8.573 ER - TY - JOUR AU - Cockcroft, DW AU - Gault, MH TI - Prediction of creatinine clearance from serum creatinine JA - Nephron PY - 1976/// VL - 16 SP - 31 EP - 41 PB - Cancer Research Campaign M3 - 10.1159/000130554 N1 - 10.1159/000130554 UR - http://dx.doi.org/10.1159/000130554 ER - TY - JOUR AU - Dobbs, NA AU - Twelves, CJ AU - Gillies, H AU - James, CA AU - Harper, PG AU - Rubens, RD TI - Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry JA - Cancer Chemother Pharmacol PY - 1995/// VL - 36 SP - 473 EP - 476 PB - Cancer Research Campaign M3 - 10.1007/BF00685796 N1 - 10.1007/BF00685796 UR - http://dx.doi.org/10.1007/BF00685796 ER - TY - JOUR AU - Duncan, R AU - Cable, HC AU - Lloyd, JH AU - Rejmanova, P AU - Kopecek, J TI - Degradation of side chains of N-(2-hydroxypropyl)methacrylamide) copolymers by lysosomal thioproteinases JA - Bioscience Rep PY - 1982/// VL - 2 SP - 1041 EP - 1046 PB - Cancer Research Campaign ER - TY - JOUR AU - Fraier, D AU - Frigerio, E AU - Pianezzola, E AU - Strolin Benedetti, M AU - Cassidy, J AU - Vasey, P TI - A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicine and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection JA - J Pharm Biomed Anal PY - 1995/// VL - 13 SP - 625 EP - 633 PB - Cancer Research Campaign ER - TY - JOUR AU - Jacquet, J-M AU - Bressolle, F AU - Galtier, M AU - Bourrier, M AU - Donadio, D AU - Jourdan, J AU - Rossi, J-F TI - Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters JA - Cancer Chemother Pharmacol PY - 1996/// VL - 27 SP - 219 EP - 225 PB - Cancer Research Campaign ER - TY - JOUR AU - Jodrell, DI AU - Reyno, LM AU - Sridhara, R AU - Eisenberger, MA AU - Tkaczuk, KH AU - Zuhowski, EG AU - Sinibaldi, VJ AU - Novak, MJ AU - Egorin, MJ TI - Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer JA - J Clin Oncol PY - 1994/// VL - 12 SP - 166 EP - 175 PB - Cancer Research Campaign ER - TY - JOUR AU - Launay Iliadis, MC AU - Bruno, R AU - Cosson, V AU - Vergniol, JC AU - Oulidaissa, D AU - Marty, M AU - Clavel, M AU - Aapro, M AU - Lebail, N AU - Iliadis, A TI - Population pharmacokinetics of docetaxel during Phase I studies using nonlinear mixed effect modelling and nonparametric maximum likelihood estimation JA - Cancer Chemother Pharmacol PY - 1995/// VL - 37 SP - 47 EP - 54 PB - Cancer Research Campaign ER - TY - JOUR AU - Maeda, H AU - Matsumura, Y TI - Tumoritropic and lymphotropic principles of macromolecular drugs JA - CRC Crit Rev Ther Drug Carrier Sys PY - 1989/// VL - 6 SP - 193 EP - 210 PB - Cancer Research Campaign ER - TY - JOUR AU - Matsumura, Y AU - Maeda, H TI - A new concept for macromolecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS JA - Cancer Res PY - 1986/// VL - 46 SP - 6387 EP - 6392 PB - Cancer Research Campaign ER - TY - JOUR AU - McLeod, HL AU - Graham, MA AU - Aamdal, S AU - Setanoians, A AU - Groot, Y AU - Lund, B TI - Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9 JA - Eur J Cancer PY - 1996/// VL - 32A SP - 1518 EP - 1522 PB - Cancer Research Campaign ER - TY - JOUR AU - Nguyen, L AU - Chatelut, E AU - Chevreau, C AU - Tranchand, B AU - Lochon, I AU - Bachaud, JM AU - Pujol, A AU - Houin, G AU - Bugat, R AU - Canal, P TI - Population pharmacokinetics of total and unbound etoposide JA - Cancer Chemother Pharmacol PY - 1998/// VL - 41 SP - 125 EP - 132 PB - Cancer Research Campaign ER - TY - JOUR AU - Piscitelli, SC AU - Rodvold, KA AU - Rushing, DA AU - Tewksbury, DA TI - Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer JA - Clin Pharmacol Ther PY - 1993/// VL - 53 SP - 555 EP - 561 PB - Cancer Research Campaign ER - TY - JOUR AU - Reyno, LM AU - Egorin, MJ AU - Eisenberger, MA AU - Sinibaldi, VJ AU - Zuhowski, EG AU - Sridhara, R TI - JA - J Clin Oncol PY - 1995/// VL - 13 SP - 2187 EP - 2195 PB - Cancer Research Campaign ER - TY - JOUR AU - Samara, E AU - Granneman, R TI - Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective JA - Clin Pharmacokinet PY - 1997/// VL - 32 SP - 294 EP - 312 PB - Cancer Research Campaign ER - TY - JOUR AU - Schoemaker, RC AU - Cohen, AF TI - Estimating impossible curves using NONMEM JA - Br J Clin Pharmacol PY - 1996/// VL - 42 SP - 283 EP - 289 PB - Cancer Research Campaign M3 - 10.1046/j.1365-2125.1996.04231.x N1 - 10.1046/j.1365-2125.1996.04231.x UR - http://dx.doi.org/10.1046/j.1365-2125.1996.04231.x ER - TY - JOUR AU - Tett, SE AU - Holford, NHG AU - McLachlan, AJ TI - Population pharmacokinetics and pharmacodynamics: an underutilised resource JA - Drug Inf J PY - 1998/// VL - 32 SP - 693 EP - 710 PB - Cancer Research Campaign ER - TY - JOUR AU - Sheiner, LB AU - Rosenberg, B AU - Marathe, VV TI - Estimation of population characteristics of pharmacokinetic parameters from routine clinical data JA - J Pharmacokinet Biopharm PY - 1977/// VL - 5 SP - 445 EP - 479 PB - Cancer Research Campaign M3 - 10.1007/BF01061728 N1 - 10.1007/BF01061728 UR - http://dx.doi.org/10.1007/BF01061728 ER - TY - JOUR AU - Yuh, L AU - Beal, S AU - Davidian, M AU - Harrison, F AU - Hester, A AU - Kowalski, K AU - Vonesh, E AU - Wolfinger, R TI - Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography JA - Biometrics PY - 1994/// VL - 50 SP - 566 EP - 575 PB - Cancer Research Campaign ER - TY - JOUR AU - Vasey, PA AU - Kaye, SB AU - Morrison, R AU - Twelves, C AU - Wilson, P AU - Duncan, R AU - Thomson, AH AU - Murray, L AU - Hilditch, TE AU - Murray, T AU - Burtles, S AU - Fraier, D AU - Frigero, E AU - Cassidy, J TI - Phase I clinical and pharmacokinetic study of PK1 (HPMA CO-Polymer doxorubicin); first member of a new class of chemotherapeutic agents - drug-polymer conjugates JA - Clin Cancer Res PY - 1999/// VL - 5 SP - 83 EP - 94 PB - Cancer Research Campaign ER -